Claims
- 1. A cell capable of at least in part complementing adenovirus E2A function of an adenovirus defective in E2A function, said cell comprising a nucleic acid encoding adenovirus E2A or a functional part thereof, derivative thereof, analogue thereof, or mixture of any of these.
- 2. The cell of claim 1 wherein said nucleic acid encoding adenovirus E2A is a temperature sensitive adenovirus.
- 3. The cell of claim 2 wherein said nucleic acid encoding adenovirus E2A is of adenovirus ts125 origin.
- 4. The cell of claim 1, claim 2, or claim 3 further comprising a nucleic acid encoding adenovirus E1-region proteins or a functional part, derivative thereof, analogue thereof, or mixture of any thereof.
- 5. The cell of claim 4 wherein said cell is of PER.C6 (ECACC deposit number 96022940) origin.
- 6. A method for producing an adenoviral particle containing an adenovirus vector with a functional deletion of E2A, said method comprising:
providing a cell according to claim 1, claim 2, claim 3, claim 4, or claim 5 with said adenovirus vector, culturing said cell, and harvesting said adenoviral particle.
- 7. The method for producing an adenoviral particle containing an adenovirus vector with a functional deletion of E2A according to claim 6 wherein said functional deletion comprises a deletion of at least part of the nucleic acid encoding E2A.
- 8. The method for producing an adenoviral particle containing an adenovirus vector with a functional deletion of E2A according to claim 6 wherein said nucleic acid encoding adenovirus E2A in said cell's genome does not comprise sequence overlap with said vector which leads to replication competent adenovirus and/or to the formation of an adenovirus vector comprising E2A function.
- 9. The method for producing an adenoviral particle according to claim 6, said method further comprising:
providing an adenovirus vector further comprising a functional deletion of E1-region encoding nucleic acid said adenovirus vector to said cell, said cell further characterized in:
being capable of at least in part complementing adenovirus E2A function of an adenovirus defective in E2A function, comprising a nucleic acid encoding adenovirus E2A or a functional part thereof, derivative thereof, and/or analogue thereof, and further comprising a nucleic acid sequence encoding adenovirus E1-region proteins or a functional part, derivative thereof, and/or analogue thereof, culturing said cell, and harvesting said virus particle.
- 10. The method according to claim 9 wherein said nucleic acid encoding adenovirus E1-region has no sequence overlap with said vector which leads to replication competent adenovirus and/or to the formation of an adenovirus vector comprising an E1 function.
- 11. A method according to claim 6, claim 7, claim 8, claim 9, or claim 10 wherein said adenovirus vector further comprises at least one nucleic acid of interest.
- 12. An adenovirus vector comprising a functional deletion of adenovirus E2A.
- 13. The adenovirus vector of claim 12 wherein said vector comprises a deletion of at least part of the nucleic acid encoding E2A.
- 14. The adenovirus vector of claim 13 wherein said deletion encompasses at least the entire coding region of E2A.
- 15. The adenovirus vector of claim 14 further comprising a deletion corresponding to a deletion of nucleotides 22443 to 24032 in adenovirus 5.
- 16. The adenovirus vector of claim 12, claim 13, claim 14, or claim 15 further comprising a deletion of nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 17. The adenovirus vector of claim 12, claim 13, claim 14, claim 15, or claim 16 wherein said deletion of nucleic acid encoding E1-region proteins comprises a deletion corresponding to a deletion of nucleotides 459 to 3510 in adenovirus 5.
- 18. The adenovirus vector of claim 12, claim 13, claim 14, claim 15, claim 16, or claim 17 further comprising at least one nucleic acid of interest.
- 19. A preparation of adenovirus vector containing adenovirus particles wherein said adenovirus vector comprises a functional deletion of E2A.
- 20. The preparation of claim 19 wherein said adenovirus vector further comprises a deletion of nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 21. The preparation of claim 19 or claim 20 free of adenovirus vectors comprising E2A function.
- 22. The preparation of claim 21, said preparation characterized in being free of adenovirus vectors comprising nucleic acid encoding a functional E2A, or a functional part, derivative and/or analogue thereof.
- 23. The preparation according to claim 21 or claim 22 free of adenovirus vectors comprising nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 24. A method for providing cells of an individual with a nucleic acid of interest, without risk of administering simultaneously a replication competent adenovirus vector, comprising administering said individual a preparation according to claim 19, claim 20, claim 21, claim 22, or claim 23.
- 25. The method of claim 24 wherein said preparation is characterized in being free of adenovirus vectors comprising nucleic acid encoding a functional E2A, or a functional part, derivative and/or analogue thereof.
- 26. The method of claim 24 or claim 25 wherein said preparation is free of adenovirus vectors comprising nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 27. An adenovirus vector comprising at least a deletion of a region which in adenovirus 5 corresponds to nucleotides 22443-24032.
- 28. An adenovirus vector comprising at least a deletion of a region which in adenovirus 5 corresponds to nucleotides 22418-24037.
- 29. An adenovirus vector comprising at least a deletion of a region which in adenovirus 5 corresponds to nucleotides 22348-24060.
- 30. An adenovirus vector according to claim 27, claim 28, or claim 29 further comprising at leastnucleic acidwhichin adenovirus 5 corresponds to nucleotides 3534-22347 and/ornucleotides 24061 until the right ITR.
- 31. An adenovirus vector according to claim 27 or claim 28 further comprising at least nucleic acid which in adenovirus 5 corresponds to nucleotides 3534-22417 and/ornucleotides 24038 until the right ITR.
- 32. An adenovirus vector according to claim 27 further comprising at least nucleic acid which in adenovirus 5 corresponds to nucleotides 3534-22442 and/or nucleotides 24033 until the right ITR.
- 33. An adenovirus vector according to claim 27 further comprising at least nucleic acid which in adenovirus 5 corresponds to nucleotides 3534-22442 and/or nucleotides 24033 until the right ITR.
- 34. The cell of claim 1 wherein said nucleic acid is integrated into said cell's genome.
- 35. The cell of claim 4 wherein said cell is derived from cell line 293.
- 36. The method according to claim 9 wherein said nucleic acid is integrated into said cell's genome.
- 37. A cell capable of at least in part complementing adenovirus E2A function of an adenovirus defective in E2A function, said cell comprising a nucleic acid encoding adenovirus E2A or a functional part thereof.
- 38. The cell of claim 37, said cell further comprising a nucleic acid encoding adenovirus E1-region proteins or a functional part thereof.
- 39. The cell of claim 38, wherein said nucleic acid encoding adenovirus E2A encodes a temperature sensitive E2A mutant.
- 40. The cell of claim 39, wherein said temperature sensitive E2A mutant is an E2A mutant encoded by adenovirus ts125.
- 41. The cell of claim 38, wherein said cell is of cell line 293 origin.
- 42. The cell of claim 39, wherein said cell is of cell line 293 origin.
- 43. The cell of claim 40, wherein said cell is of cell line 293 origin.
- 44. A method for producing an adenoviral particle containing an adenovirus vector with a functional deletion of E2A, said method comprising:
providing a cell according to any one of claims 37-43 with said adenovirus vector, culturing said cell, and harvesting said adenoviral particle.
- 45. The method according to claim 44, wherein said functional deletion comprises a deletion of at least part of the nucleic acid encoding E2A.
- 46. The method according to claim 45, wherein said nucleic acid encoding adenovirus E2A in said cell's genome does not comprise sequence overlap with said vector which leads to replication competent adenovirus and/or to the formation of an adenovirus vector comprising E2A function.
- 47. The method according to claim 45, said method further comprising:
providing an adenovirus vector further comprising a functional deletion of E1-region encoding nucleic acid said adenovirus vector to said cell, said cell further characterized by:
being capable of at least in part complementing adenovirus E2A function of an adenovirus defective in E2A function, comprising a nucleic acid encoding adenovirus E2A or a functional part thereof, derivative thereof, and/or analogue thereof, and further comprising a nucleic acid sequence encoding adenovirus E1-region proteins or a functional part, derivative thereof, and/or analogue thereof, culturing said cell, and harvesting said virus particle.
- 48. An adenovirus vector comprising a functional deletion of adenovirus E2A.
- 49. The adenovirus vector of claim 48 wherein said vector comprises a deletion of at least part of the nucleic acid encoding E2A.
- 50. The adenovirus vector of claim 49 wherein said deletion encompasses at least the entire coding region of E2A.
- 51. The adenovirus vector of claim 48, further having a deletion of nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 52. The adenovirus vector of claim 49, further having a deletion of nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 53. The adenovirus vector of claim 50 further having a deletion of nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 54. A preparation of adenovirus vector containing adenovirus particles wherein said adenovirus vector has a functional deletion of E2A.
- 55. The preparation of claim 54 wherein said adenovirus vector further has a deletion of nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 56. The preparation of claim 54 free of adenovirus vectors comprising E2A function.
- 57. The preparation of claim 55 free of adenovirus vectors comprising E2A function.
- 58. The preparation of claim 56, said preparation characterized in being free of adenovirus vectors comprising nucleic acid encoding a functional E2A, or a functional part, derivative and/or analogue thereof.
- 59. The preparation of claim 57, said preparation characterized in being free of adenovirus vectors comprising nucleic acid encoding a functional E2A, or a functional part, derivative and/or analogue thereof.
- 60. The preparation of claim 56, free of adenovirus vectors comprising nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 61. The preparation of claim 57, free of adenovirus vectors comprising nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 62. The preparation of claim 58, free of adenovirus vectors comprising nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 63. The preparation of claim 59 free of adenovirus vectors comprising nucleic acid encoding E1-region proteins or parts, derivatives and/or analogues thereof.
- 64. A method for providing cells of a subject with a nucleic acid of interest, with a decreased risk of administering simultaneously a replication competent adenovirus vector, said method comprising administering to the subject's cells the preparation of any one of claims 54-63.
- 65. An adenovirus vector comprising at least a deletion of a region which in adenovirus 5 corresponds to nucleotides 22443-24032, or nucleotides 22418-24037, or nucleotides 22348-24060, further comprising at least nucleic acid which in adenovirus 5 corresponds to nucleotides 3534-22347 and/or nucleotides 24061 until the right ITR.
- 66. The method according to claim 44, wherein said nucleic acid is integrated into said cell's genome.
- 67. The method according to claim 45, wherein said nucleic acid is integrated into said cell's genome.
- 68. The method according to of claim 46, wherein said nucleic acid is integrated into said cell's genome.
- 69. The method according to claim 47, wherein said nucleic acid is integrated into said cell's genome.
Priority Claims (2)
Number |
Date |
Country |
Kind |
95201611.1 |
Jun 1995 |
EP |
|
95201728.3 |
Jun 1995 |
EP |
|
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Ser. No. 09/298,745, now U.S. Pat. No. ______, incorporated by reference, which is a continuation-in-part of U.S. patent application No. 08/793,170 filed Mar. 25, 1997, pending, incorporated herein by reference, which is the national stage filing of PCT/NL96/00244 filed Jun. 14, 1996, incorporated herein by reference, claiming priority from EP 95201611.1 filed June 15, 1995 and EP 95201728.3 filed Jun. 26, 1995, all of which are incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09298745 |
Apr 1999 |
US |
Child |
10136139 |
May 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08793170 |
Mar 1997 |
US |
Child |
09298745 |
Apr 1999 |
US |